Menu
Investment to date in
portfolio entities
“Undruggable” targets successfully “drugged”
Investment to date in
portfolio entities
“Undruggable” targets successfully “drugged”
Our goal is to bring drug candidates with novel mechanisms of action to a stage closer to clinical translation, making them more suitable for strategic co-development. We are developing small molecule drugs that demonstrate target engagement and deliver a profound disease-modifying effect.
Our discovery platform can tailor novel and clinically relevant compounds for some of the most exciting targets that remain out of therapeutic reach. We focus on clinically validated targets, leveraging cutting-edge biophysical and orthogonal technologies, solving high-resolution atomic resolution structures of drugs in complex with their protein targets to accelerate the discovery process.
We focus on novel diseases targets with validated clinical relevance that fit our discovery platform. This offers an unmatched potential in revolutionizing the standard of care.
By merging cell and structure-based data with information-driven strategies, we have built a cutting-edge drug discovery engine.
We harness advanced structural biology, biochemical, and biophysical technologies to design first-in-class therapeutics against clinically relevant drug targets.
Pledge has an international footprint with presence in two of the most innovative ecosystems in the US and EU. We are headquartered in the Greater Boston area in the US and also have research labs in Flanders, Belgium.
